Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Montpellier
Clinical trial register · France

Clinical Trials in Montpellier, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 68 Marseille 36 Bordeaux 35 Montpellier 32 Lille 31
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Montpellier169 AstraZeneca61 Institut du Cancer de Montpellier - Val d'Aurelle59 Novartis Pharmaceuticals32 Hoffmann-La Roche32 Clear sponsor filter
Site location
Paris68 Marseille36 Bordeaux35 Montpellier32 Lille31
All 73 locations
Target enrolment
to

Trials with a site in Montpellier

32 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
650
Bordeaux, Brest, Montpellier, Paris, Pierre-Bénite, Rouen
2026-04-16
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Angers, Marseille, Montpellier
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Limoges, Ajaccio, Amiens, Clermont-Ferrand, Grenoble, Lille, Montpellier, Nancy
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Angers, Bron, Dijon, Montpellier, Paris, Toulouse, Tours
2025-10-09
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Chambray-lès-Tours, Montpellier, Nantes, Pessac, Poitiers
2025-10-03
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Bron, Clichy, Montpellier, Nantes, Pessac, Toulouse
2025-05-30
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Grenoble, Montpellier, Paris, Pierre-Bénite
2025-05-22
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Béziers, Cholet, Grenoble, Lille, Montpellier, Paris, Pessac, Poitiers
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Montpellier, Nancy, Rennes
2025-02-24
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Bron, Montpellier, Nancy, Rennes
2024-12-12
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Bordeaux, Dijon, Lille, Lyon, Montpellier, Paris, Rennes, Strasbourg
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Angers, Brest, Clamart, Grenoble, Montpellier, Nice, Pessac, Poitiers
2024-10-24
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Dijon, Le Mans, Lille, Montpellier, Paris, Rennes, Strasbourg, Toulouse
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Bordeaux, Clermont-Ferrand, Marseille, Montpellier, Nantes, Paris, Strasbourg, Toulouse
2024-09-04
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Montpellier, Paris, Toulouse
2024-05-21
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Grenoble, Montpellier, Nantes, Paris, Pierre-Bénite, Rouen, Toulouse
2023-12-07
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Angers, Bordeaux, Bron, Caen, Dijon, Lille, Marseille, Montpellier
2023-11-24
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Marseille, Montpellier, Paris, Rennes, Toulouse
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Montpellier, Paris, Toulouse, Tours
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Angers, Antony, Bordeaux, Brest, Montpellier, Nice, Paris, Pierre-Bénite
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Marseille, Bron, Montpellier, Saint-Herblain, Strasbourg
2022-12-06
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Lille, Marseille, Montpellier
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Dijon, Montpellier, Paris
2022-01-27
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Besançon, Clermont-Ferrand, La Roche-sur-Yon, Lyon, Marseille, Montpellier, Paris, Valenciennes
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Le Kremlin-Bicêtre, Montpellier, Strasbourg
2021-10-05
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Marseille, Montpellier, Paris
2021-09-20
Recruiting
Novartis Pharmaceuticals
Phase 1/2
222
Montpellier, Bordeaux, Clermont-Ferrand, Marseille, Vandœuvre-lès-Nancy
2021-07-30
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Lille, Marseille, Montpellier, Paris
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nantes, Paris, Strasbourg, Vandœuvre-lès-Nancy
2021-06-09
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Montpellier, Paris, Toulouse
2019-10-03
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Lille, Montpellier, Nantes, Nice, Nîmes, Paris, Strasbourg
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Bordeaux, Le Kremlin-Bicêtre, Marseille, Montpellier, Toulouse
2013-07-26
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 October 2026. https://priyalifescience.com/clinical-trials-france/city/montpellier

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Montpellier that also match the filters currently applied.

How many clinical trials are recruiting in Montpellier?

15 of the 32 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Montpellier), 32 studies
PhaseStudiesRecruitingShare
Phase 3191059.4%
Phase 27221.9%
Phase 1/25215.6%
Phase 2/3113.1%

Most active sponsors

Lead sponsors with the most studies (Montpellier)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3215
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.